CN109077302A - A kind of medical food and preparation method thereof treating and preventing old aged muscle decaying syndrome - Google Patents
A kind of medical food and preparation method thereof treating and preventing old aged muscle decaying syndrome Download PDFInfo
- Publication number
- CN109077302A CN109077302A CN201810791304.2A CN201810791304A CN109077302A CN 109077302 A CN109077302 A CN 109077302A CN 201810791304 A CN201810791304 A CN 201810791304A CN 109077302 A CN109077302 A CN 109077302A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- syndrome
- treating
- medical food
- old aged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003205 muscle Anatomy 0.000 title claims abstract description 66
- 235000013305 food Nutrition 0.000 title claims abstract description 52
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 235000016709 nutrition Nutrition 0.000 claims abstract description 19
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229940088594 vitamin Drugs 0.000 claims abstract description 17
- 229930003231 vitamin Natural products 0.000 claims abstract description 17
- 235000013343 vitamin Nutrition 0.000 claims abstract description 17
- 239000011782 vitamin Substances 0.000 claims abstract description 17
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 16
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 14
- 239000011707 mineral Substances 0.000 claims abstract description 14
- 235000010755 mineral Nutrition 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 229960003624 creatine Drugs 0.000 claims abstract description 9
- 239000006046 creatine Substances 0.000 claims abstract description 9
- -1 beta-hydroxy-methylbutanoic acid calcium Chemical compound 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- 235000018102 proteins Nutrition 0.000 claims description 21
- 235000019197 fats Nutrition 0.000 claims description 15
- 102000015636 Oligopeptides Human genes 0.000 claims description 14
- 108010038807 Oligopeptides Proteins 0.000 claims description 14
- 235000014633 carbohydrates Nutrition 0.000 claims description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 239000003921 oil Substances 0.000 claims description 11
- 235000019198 oils Nutrition 0.000 claims description 11
- 241000209140 Triticum Species 0.000 claims description 9
- 235000021307 Triticum Nutrition 0.000 claims description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 229930091371 Fructose Natural products 0.000 claims description 8
- 239000005715 Fructose Substances 0.000 claims description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 8
- 239000005913 Maltodextrin Substances 0.000 claims description 7
- 229920002774 Maltodextrin Polymers 0.000 claims description 7
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 7
- 229920000294 Resistant starch Polymers 0.000 claims description 7
- 229940035034 maltodextrin Drugs 0.000 claims description 7
- 235000021254 resistant starch Nutrition 0.000 claims description 7
- 239000010495 camellia oil Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 235000013325 dietary fiber Nutrition 0.000 claims description 6
- 235000021323 fish oil Nutrition 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 6
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims description 5
- 108010084695 Pea Proteins Proteins 0.000 claims description 5
- 229940108924 conjugated linoleic acid Drugs 0.000 claims description 5
- 230000036571 hydration Effects 0.000 claims description 5
- 238000006703 hydration reaction Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 235000019702 pea protein Nutrition 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- 241000251468 Actinopterygii Species 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 4
- 229910021556 Chromium(III) chloride Inorganic materials 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 229960001231 choline Drugs 0.000 claims description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 4
- 229960000359 chromic chloride Drugs 0.000 claims description 4
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 claims description 4
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 229940055726 pantothenic acid Drugs 0.000 claims description 4
- 235000019161 pantothenic acid Nutrition 0.000 claims description 4
- 239000011713 pantothenic acid Substances 0.000 claims description 4
- 239000011772 phylloquinone Substances 0.000 claims description 4
- 239000001508 potassium citrate Substances 0.000 claims description 4
- 229960002635 potassium citrate Drugs 0.000 claims description 4
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 4
- 235000011082 potassium citrates Nutrition 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 239000011781 sodium selenite Substances 0.000 claims description 4
- 229960001471 sodium selenite Drugs 0.000 claims description 4
- 235000015921 sodium selenite Nutrition 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 239000011691 vitamin B1 Substances 0.000 claims description 4
- 239000011715 vitamin B12 Substances 0.000 claims description 4
- 239000011716 vitamin B2 Substances 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 239000011647 vitamin D3 Substances 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 240000004760 Pimpinella anisum Species 0.000 claims description 3
- 235000012550 Pimpinella anisum Nutrition 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 239000004225 ferrous lactate Substances 0.000 claims description 3
- 235000013925 ferrous lactate Nutrition 0.000 claims description 3
- 229940037907 ferrous lactate Drugs 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 229940118149 zinc sulfate monohydrate Drugs 0.000 claims description 3
- RNZCSKGULNFAMC-UHFFFAOYSA-L zinc;hydrogen sulfate;hydroxide Chemical compound O.[Zn+2].[O-]S([O-])(=O)=O RNZCSKGULNFAMC-UHFFFAOYSA-L 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 235000013734 beta-carotene Nutrition 0.000 claims description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 2
- 239000011648 beta-carotene Substances 0.000 claims description 2
- 229960002747 betacarotene Drugs 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 229940108925 copper gluconate Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- VLAPMBHFAWRUQP-UHFFFAOYSA-L molybdic acid Chemical compound O[Mo](O)(=O)=O VLAPMBHFAWRUQP-UHFFFAOYSA-L 0.000 claims description 2
- NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical compound O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- 229940099596 manganese sulfate Drugs 0.000 claims 1
- 239000011702 manganese sulphate Substances 0.000 claims 1
- 235000007079 manganese sulphate Nutrition 0.000 claims 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 claims 1
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 claims 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 22
- 208000001076 sarcopenia Diseases 0.000 abstract description 16
- 230000035764 nutrition Effects 0.000 abstract description 11
- 239000000203 mixture Substances 0.000 abstract description 5
- 235000015097 nutrients Nutrition 0.000 abstract description 5
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 3
- 229930195729 fatty acid Natural products 0.000 abstract description 3
- 239000000194 fatty acid Substances 0.000 abstract description 3
- 150000004665 fatty acids Chemical class 0.000 abstract description 3
- 238000005457 optimization Methods 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 150000004671 saturated fatty acids Chemical class 0.000 description 7
- 230000007423 decrease Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 208000002720 Malnutrition Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000001071 malnutrition Effects 0.000 description 4
- 235000000824 malnutrition Nutrition 0.000 description 4
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 4
- 208000015380 nutritional deficiency disease Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000008934 Muscle Proteins Human genes 0.000 description 2
- 108010074084 Muscle Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 101710094902 Legumin Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000017434 Torsin Human genes 0.000 description 1
- 108050005633 Torsin Proteins 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- LKDRXBCSQODPBY-ZXXMMSQZSA-N alpha-D-fructopyranose Chemical compound OC[C@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-ZXXMMSQZSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- YZHOZVWZUXBPMD-UHFFFAOYSA-N calcium;3-hydroxy-3-methylbutanoic acid Chemical compound [Ca].CC(C)(O)CC(O)=O YZHOZVWZUXBPMD-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- MZNYADCLSDCSHV-UHFFFAOYSA-N sulfuric acid;zinc;hydrate Chemical compound O.[Zn].OS(O)(=O)=O MZNYADCLSDCSHV-UHFFFAOYSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000005496 tempering Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention provides a kind of medical food and preparation method thereof for the treatment of and prevention old aged muscle decaying syndrome.Based on the special medicine purposes formula food 1000ml, the nutrient includes: protein 56-82g, fat 20-31g, carbohydrate 110-160g, vitamin 1.5-2.6g, minerals 20-30g, water 690-800g;The present invention provides a kind of specific full nutrition special medicine purposes formula food for sarcopenia patient containing beta-hydroxy-methylbutanoic acid calcium and creatine rich in small peptide class high-quality protein, optimization Fatty acids composition by reasonable raw material proportioning and use.The present invention has good preventive and therapeutic action to the elderly's sarcopenia, can delay the occurrence and development of sarcopenia.
Description
Technical field
The invention belongs to medical screen technical field, in particular to a kind for the treatment of and prevention old aged muscle decaying syndrome
Medical food and preparation method thereof is suitable for the elderly and muscle depletion syndrome patients, by tube feed or takes orally, as single
Source of nutrition provides nutritional support for patient.
Technical background
On May 1st, 2011, China National Bureau of Statistics of China disclose sixth national census as a result, announcing that China is comprehensive
Into ageing stage.Related newest result of study shows, it is contemplated that the population to the year two thousand fifty whole world 60 years old or more will be more than 20
Hundred million, and wherein 500,000,000 populations are in China.With age, the great change that body occurs is exactly the skeletal muscle of duration
The decline of Mass lost and muscular strength and body function.It began to suffer from muscle decaying at 50 years old researches show that there are about the people of 1%-2%
Disease, the people of 5%-13% suffered from muscle decaying disease at 60-70 years old;And suffer within 80 years old or more muscle decaying disease crowd then more than 50%.
Sarcopenia (Sarcopenia) is that progressive skeletal muscle amount relevant to age is increased is reduced, with muscular force
Amount and (or) the syndrome of muscle function decline.A large amount of studies have shown that muscle decaying will lead to muscle strength decrease, activity subtracts
Less, the problems such as being easy tumble, quality of life decline, additionally increases having diabetes, heart and brain blood systemic disease, osteoporosis etc.
The danger of disease brings heavy financial burden to health delivery system and society.
As China enters the aging of population stage, people are fully recognized that the harm of sarcopenia and carry out product
Pole prevention and treatment is of great significance to improving life of elderly person quality, reducing complication.
The reason of causing muscle to be decayed, has very much, wherein mainly due to energy or protein insufficiency of intake, gastrointestinal tract function
Can disorder, caused by Disorder of Digestion and A orption.Wherein protein malnutrition is one of its main risk factor.With the age
Increase, the ability of body itself synthetic proteins matter reduces, and catabolism activity enhancing, digestive function decline etc. leads to the elderly's egg
The uptake and utilization rate of white matter decline.
Nutritional supplementation is to improve one of old aged muscle decaying major way.Studies have shown that carrying out science equilibrium to patient
Nutritional intervention effectively can prevent and delay muscle attenuation process.
Special medicine purposes formula food (Foods for Special Medical Purpose, FSMP), referred to as special doctor
Food is to meet limited feed, Disorder of Digestion and A orption, metabolic disorder or particular disease states crowd to nutrient or diet
Special requirement, specially process the formula food being formulated.
It is used for the enteral nutrition food squeeze of " sarcopenia " patient, existing a few money products currently on the market
It is not designed directed entirely to physiology, nutritional character and the demand of muscle decaying disease patient, cannot effectively improve patient battalion
Defective mode is supported, to inhibit and reverse the generation of the various complication as caused by protein malnutrition.Meanwhile materials are not
Meet " special medicine purposes formula food " (GB29922) related request.
Summary of the invention
In view of the above-mentioned problems, requirement of the present invention according to GB29922, in conjunction with the physilogical characteristics of muscle depletion syndrome patients
And nutritional need, the research achievements such as comprehensive newest nutrition, clinical medicine and fundamental biological knowledge, using hydrolyzing lactoalbumin, pea
Legumin peptide, wheat oligopeptide, ocean fish oligopeptide powder and leucine provide nitrogen source, other is cooperated to provide carbohydrate and rouge
Raw material and dietary fiber, the multivitamin and minerals of fat, not only serving as single nutrient source is sarcopenia
Patient provides comprehensively and balanced nutrition, additionally it is possible to promote the increase of body musculature and the enhancing of muscle strength, Neng Gouyou
The improvement of effect and the muscle decay for inhibiting sarcopenia patient.
Above-mentioned purpose of the invention is achieved through the following technical solutions:
The present invention provides a kind of medical food for the treatment of and prevention old aged muscle decaying syndrome, by the medical food
1000ml meter, include: protein 56-82g, fat 20-31g, carbohydrate 110-160g, dietary fiber 10.5-16.2g,
Beta-hydroxy-methylbutanoic acid calcium 0.9-1.6g, creatine 2.2-3.2g, vitamin 1.5-2.6g, minerals 20-30g and water 690-
800g;
Wherein, the protein includes hydrolyzing lactoalbumin 22-36g, pea protein peptide 13-20g, wheat oligopeptide 13-
20g, ocean fish oligopeptide powder 4.2-6.5g, leucine 1.6-2.5g;
The fat includes medium chain triglyceride 7.2-11.5g, tea seed oil 5.5-8.5g, rapeseed oil 4.5-7.0g, is total to
Conjugated linoleic acid 1.5-2.5g, fish oil 2.0-3.5g;
The carbohydrate includes maltodextrin 70-105g, fructose 22-35g, resistant starch 13-20g;
The vitamin includes vitamin A 3.1-4.5mg, vitamin C 1.1-1.58g, vitamin D3 16.5-24μg、
Vitamin E 55-82mg, vitamin K11142-205 μ g, vitamin B14.2-6.5mg, vitamin B25.6-8.2mg, dimension life
Plain B65.6-8.2mg, pantothenic acid 13.9-21.2mg, biotin 8.5-12.5mg, folic acid 7.5-10.5mg, niacinamide 19.5-
28.2mg, vitamin B126.2-8.9ug, choline 330-479mg;
The minerals include calcium chloride 2.4-3.6g, potassium hydroxide 0.3-0.49g, potassium citrate 0.96-1.55g, phosphorus
Sour hydrogen dipotassium 3.3-5.2g, sodium citrate 4.0-6.5g, magnesium chloride 2.1-3.2g, six hydrated chromium trichloride 13.5-18.6mg, Portugal
Grape saccharic acid copper 18.2-28.5mg, three hydration ferrous lactate 80.5-118.2mg, Manganous sulfate monohydrate 11.2-17.9mg, two hydrations
Sodium molybdate 7.5-11.6mg, sodium selenite 26.6-40.2mg, Zinc sulfate monohydrate 40.9-60.5mg, 10% potassium iodide 2.8-
4.2g。
Preferably, the medical food for treating and preventing old aged muscle decaying syndrome includes protein 65g, fat
34.5g, carbohydrate 126g, dietary fiber 12.4g, vitamin 2.0g, minerals 24g, water 770g.
Preferably, the protein include hydrolyzing lactoalbumin 28g, pea protein peptide 15.2g, wheat oligopeptide 15.2g,
Leucine 2.0g.
Preferably, the fat includes medium chain triglyceride 8.5g, tea seed oil 6.5g, rapeseed oil 5.3g, the sub- oil of conjugation
Sour 1.9g, fish oil 2.5g.
Preferably, the carbohydrate includes maltodextrin 85g, fructose 26g, resistant starch 15g;It also include oligomeric fruit
Sugared 3.6g, xylo-oligosaccharide 3.6g, isomaltose 12.4g.
Preferably, the vitamin includes vitamin A 3.62mg, vitamin C 1.26g, vitamin D319.2 μ g, dimension
Raw element E 64mg, vitamin K1160 μ g, vitamin B14.8mg, vitamin B26.4mg, vitamin B66.4mg, pantothenic acid
16.64mg, biotin 9.6mg, folic acid 8.0ug, niacinamide 22.4mg, vitamin B127.04 μ g, choline 380mg.
Preferably, the minerals include calcium chloride 2.8g, potassium hydroxide 0.4g, potassium citrate 1.2g, dipotassium hydrogen phosphate
4.0g, sodium citrate 5.0g, magnesium chloride 2.5g, six hydrated chromium trichloride 14.35mg, copper gluconate 21.25mg, three hydration creams
Sour ferrous iron 93.85mg, Manganous sulfate monohydrate 14.0mg, two molybdic acid hydrate sodium 8.83mg, sodium selenite 32.2mg, sulfuric acid monohydrate
Zinc 48.03mg, 10% potassium iodide 3.3g.
Preferably, the medical food for treating and preventing old aged muscle decaying syndrome includes beta-hydroxy-methylbutanoic acid
Calcium 1.2g and creatine 2.5g.
Preferably, nutritional agents described in the medical food for treating and preventing old aged muscle decaying syndrome includes emulsifier
Soybean lecithin 1.1-1.8g, acidity regulator citric acid 1.7-2.6g, colorant natural Beta-carotene 0.7-1.2g.
The energy supply ratio of special medicine purposes formula food protein of the present invention, fat and carbohydrate is 25:25:
50。
The present invention also provides the preparation methods of the special medicine purposes food described in one kind, comprising the following steps:
(1) aniseed dissolves: the pure water of total amount 65%-75% being added in dissolving tank, will consolidate under strong Vibratory Mixing
Body raw material is sequentially added into dissolving tank, so that feed liquid is flowed back uniformly by carrying out under liquid level, is uniformly dispersed in pure water, together
When avoid generating excessive bubble and feed liquid layering.Nitrogen is constantly passed through into lotion in entire process for preparation;
(2) oil is mutually prepared: oils raw material and liposoluble vitamin being mixed well dissolution in order, are heated to 40-60 DEG C;
(3) 60 DEG C or so progress homogeneous homogeneous: are cooled to after water phase is mutually mixed well with oil;
It (4) will be filling after the feed liquid cooling after homogeneous;
(5) terminal sterilization: being placed in rotation for product, sterilize in fountain sterilizing cabinet, and 121 DEG C of sterilising temp, F0 value 8-12,
Obtain finished product.
Special medicine purposes formula food of the present invention increases and muscle decaying caused by malnutrition for the age
Syndrome patients.Special medicine purposes formula food of the present invention includes the nutrient that human body needs, i.e. carbohydrate, rouge
Fat, proteins,vitamins,minerals, water meet " Dietary Reference Intakes of Chinese Residents ", and nutrition is comprehensive, proportion is equal
Weighing apparatus.Small peptide that is high-quality and being not required to digest and can directly be absorbed by organisms all is selected to provide nitrogen source in the present invention.These small peptides
The nitrogen source bioavailability of class is far superior to whole albumen.Therefore, can be low for digestive function, the muscle decaying that protein lacks
Syndrome patients provide optimal nitrogen source.Fatty acid composition is optimized simultaneously, provides a variety of fatty acid of proportion science for body.
The special medicine purposes formula food of the present invention has been especially added with creatine and beta-hydroxy-Beta-methyl fourth
Sour calcium can promote the synthesis of muscle and the raising of muscle strength.The special medicine purposes formula food of the present invention
Carbohydrate source in maltodextrin, fructose and resistant starch.On USA Magazine " Clinical Endocrinology and metabology "
An investigation point out that the intake of excessive fructose may cause hepatic injury, aggravate burden of liver, and be converted into fatty liver, in turn
Cause hyperlipidemia.Therefore, fructose additive amount is limited in the present invention, and suitable fructose and maltodextrin, resistant starch are arranged in pairs or groups
It uses, can prevent postprandial blood sugar from quickly increasing.Wherein, maltodextrin needs not move through the hydrolysis of ptyalin, can directly into
Enter in stomach, is further digested and assimilated through small intestinal mucosa enzyme, can be relieved pipe intestinal digesting pressure.Fructose is as chemical activity in carbohydrate
Highest sugar, metabolism in vivo is faster than glucose, is easy to be absorbed by organisms, and can be used as the mouth that sweetener adjusts product
Sense;Resistant starch has the glucose-lipid metabolism disorder for improving diabetic, improves insulin sensitivity, antagonism or mitigation pancreas islet
The effect that element is resisted, and tolerance it is good, it is edible after less there are the adverse reactions such as diarrhea, abdominal distension.
It is well known that the intake of high protein is not required in that building musculature, and the quality of protein is only
Key factor.Therefore, the quality of protein decays to the synthesis of muscle protein, reduction body muscle than the supply amount of protein
It is even more important.With sepg whey albumen, wheat oligopeptide, pea protein peptide, ocean fish oligopeptide and leucine etc. in the present invention
High-quality protein is nitrogen source, is more advantageous to the absorption and utilization of body, can be caused by effective torsin protein matter malnutrition
The negative nitrogen balance of sarcopenia patient.Wherein, hydrolyzing lactoalbumin is by hydrolyzed whey protein using protease at short
The mixture of peptide and amino acid, can be directly by small intestinal absorption.Branched-chain amino acid rich in, branched-amino in lactalbumin
Acid can promote muscle to synthesize, and reduce muscle breakdown, to holding and repair musculature important role.Wheat oligopeptide has
Conducive to the growth of gastric epithelial cells, mitigates the denaturation of gastrointestinal mucosa epithelial cell, necrosis, maintain the structure and function of gastrointestinal mucosa
Can, peomote the digestion and absorption of food ingredients.In wheat oligopeptide used in the present invention containing 25% or more paddy
Glutamine (Gln).Glutamine can increase the volume of muscle cell as a kind of conditionally essential amino acid, inhibit albumen point
Solution promotes muscle growth.Therefore, the present invention uses wheat oligopeptide, is providing oligopeptide easy to digest as high-quality protein source
While, enough glutamine are provided for body, the synthesis of body musculature can be promoted.Leucine, as a kind of people
Body essential amino acid is the important regulating and controlling factor of whole body and skeletal muscle protein synthesis.
Saturated fatty acid, the monounsaturated fatty acids that fat in special medicine purposes formula food of the present invention includes
And polyunsaturated fatty acid ratio is 1:1:1.Wherein, saturated fatty acid comes from medium chain triglyceride, and medium chain triglyceride has
It digests and assimilates fastly in vivo, energy is easy to the characteristics of discharging.Since medium chain triglyceride is rapid in liver metabolism, will not synthesize again
Triglycerides, therefore will not be stored in liver, it is smaller to the metabolic burden of liver.
Monounsaturated fatty acids in unsaturated fatty acid is mainly from tea seed oil and rapeseed oil.The study found that tealeaves
Unsaturated fatty acid content is up to 82% or more in seed oil, and wherein monounsaturated fatty acids can be adjusted effectively immune up to 50%
Competent cell enhances body's immunity.Rapeseed oil mid-oleic up to 60% or more, with peanut oil, corn oil, soybean oil,
Olive oil etc. is compared, and saturated fatty acid content is minimum, and contains reasonable linoleic acid plus linolenic acid, is referred to as in the world " most
The edible vegetable oil of health ".Research in recent years, which shows conjugated linoleic acid (CLA), has reduction animal and body fat, increases muscle
Effect.Dietary supplements be can be used as preventing muscle decaying syndrome.Fish oil is rich in EPA and DHA, is adjustable immune anti-
It answers.Scientist indicates that DHA can reduce internal level of inflammation, improves the ability by tempering enhancing muscle, prevents the elderly's muscle
Atrophy, prevention muscle decaying syndrome.
Chinese Soclety of Nutrition suggests, fat institute should be no more than always for the 30% of energy for energy, wherein saturated fatty acid, list
Unsaturated fatty acid and polyunsaturated fatty acid institute for energy respectively account for 10% or so.In the present invention, with reference to Nutrition Society for rouge
Fat energizes ratio, limits formula total lipid content, optimizes saturated fatty acid, monounsaturated fatty acids and polyunsaturated fat
Sour ratio.The total fat energy supply of end formulation setting is 20% or so, at the same by medium chain triglyceride, tea seed oil, rapeseed oil,
The scientific matching that fish oil, conjugated linoleic acid and phytosterin ester various plants oil carry out so that saturated fatty acid in product, it is single not
Saturated fatty acid and polyunsaturated fatty acid ratio are 1:1:1.
Dietary fiber oligofructose etc. used in the present invention can be used as prebiotics and promote the growth of probiotics in enteron aisle numerous
It grows, inhibits the growth of spoilage organisms, while one of protective barrier can be formed in intestinal mucosal surface, reduce to intestinal toxic substance
It absorbs, intestines peristalsis can also be promoted, accelerate the discharge of intestinal toxic substance, reduce the hair of sarcopenia tients with constipation
It is raw, enhance immunity of organisms.
The special medicine purposes formula food of the present invention also includes new raw-food material beta-hydroxy-Beta-methyl butyric acid
Calcium (HMB-Ca) and creatine.Wherein, beta-hydroxy-β-methyl butyrate (HMB) is the metabolite of branched-chain amino acid leucine, to flesh
The quality and strength of meat have improvement result, can promote the growth of muscle volume, moreover it is possible to enhance human body nitrogen fixing capacity, maintain body
Internal protein is horizontal.Creatine can be synthesized in vivo by arginine, glycine and methionine.It can be by increasing phosphoric acid in muscle
Creatine and glycogen, quickly increase muscle strength, promote the growth of new flesh, and accelerate fatigue recovery.
By adequately studying and literature search, the present invention are finally added to suitable vitamin and mineral in formula
Matter, including macroelement, essential trace element, liposoluble vitamin and water soluble vitamin.Vitamin and mineral in the present invention
The selection of matter raw material and additive amount meet " food additives use standard " (GB2760) and " food enrichment use is defended
Raw standard " (GB14880) requirement.In formula, multivitamin and minerals are used cooperatively, can substance to body and
Important adjustment effect is played in energetic supersession.
Specific embodiment
To make those skilled in the art more fully understand technical solution of the present invention, below with reference to embodiment to the present invention
A kind of medical food and preparation method thereof of the treatment and prevention old aged muscle decaying syndrome provided is described in detail.
1. raw material feeds intake as shown in table 1:
Table 1: nutritional agents of the present invention prepares raw material
Preparation method:
(1) aniseed dissolves: the pure water of total amount 65-75% being added in dissolving tank, by solid under strong Vibratory Mixing
Raw material is sequentially added into dissolving tank, so that feed liquid is flowed back uniformly by carrying out under liquid level, is uniformly dispersed in pure water, simultaneously
It avoids generating excessive bubble and feed liquid layering.Nitrogen is constantly passed through into lotion in entire process for preparation.
(2) oil is mutually prepared: oils raw material and liposoluble vitamin being mixed well dissolution in order, are heated to 40-60 DEG C.
(3) 60 DEG C or so progress homogeneous homogeneous: are cooled to after water phase is mutually mixed well with oil.
It (4) will be filling after the feed liquid cooling after homogeneous.
(5) terminal sterilization: being placed in rotation for product, sterilize in fountain sterilizing cabinet, and 121 DEG C of sterilising temp, F0 value 8-12,
Obtain finished product.
The purposes of special medicine purposes described in embodiment formula food is to sarcopenia mouse species experimental study
Test objective: special medicine purposes formula food described in embodiment is explored to sarcopenia mouse muscle
The influence of decay
Test method: 8-10 week old C57BL/6 male mice is taken, muscle depletion syndrome is established by induced by dexamethasone
Model will model successful mouse totally 30, be randomly divided into 2 groups, every group 15.Test group feeds special doctor described in embodiment
Learn formula food, control group feed equal heats, etc. nitrogen quantity routine enteral nutrition emulsion.Edible dosage is 0.3g/ days, is fed daily
Mouse, free water continue 21 days.
Testing index:
(1) weight and muscle quality detection: before intervention, each group mouse weight is weighed respectively and detects its muscle quality;Examination
It tests after beginning and detects mouse muscle quality using Echo MRI weekly;After last time is intervened, weighs and detect muscle quality;
(2) muscle strength detects: before intervention, detecting mouse grip using grip instrument, after intervention, detects mouse again
Grip;
Statistical method: being examined using t between group, and p value is less than or equal to 0.05 and thinks that the difference examined is statistically significant.
Test result:
(1) influence of the special medicine purposes formula food to mouse weight, muscle quality and weight ratio described in embodiment;
Influence (n=15, x ± s) of the special medicine purposes formula food described in 2 embodiment 1 of table to mouse weight
Note: compared with the control group, a P < 0.05
Special medicine purposes formula food described in 3 embodiment of table influences (n=to the ratio of mouse muscle quality and weight
15, x ± s)
Note: compared with the control group, a P < 0.05
(2) influence of the special medicine purposes formula food to mouse grip described in embodiment
Influence (n=15, x ± s) of the special medicine purposes formula food described in 4 embodiment of table to mouse grip
Note: compared with the control group, a P < 0.05
Result of study
(1) as shown in tables 2 and 3, before intervention, two groups of mouse weights are without significant difference (p > 0.05);After intervention, test group
Mouse weight is significantly higher than control group weight (P < 0.05);As shown in table 2, after excluding weight influence, the muscle quality of test group
It is significantly higher than the ratio (P < 0.05) of control group muscle quality and weight with the ratio of weight;Show the special full nutrient formulation
Food can provide sufficient nutrition for mouse, increase its weight, while can increase the muscle mass of body;
(2) as shown in table 4, control group and test group mouse grip all increased after intervention, illustrate that nutritional supplementation can
Improve the muscle strength of sarcopenia mouse;And after intervening, the grip of test group mouse is shown compared with control group group
It writes and increases, illustrate that special medicine purposes formula food described in the embodiment can effectively improve the muscle strength of mouse.
In conclusion the experiment show the special medicine purposes formula food compared with commercially available common enteral nutrition product,
The nutrition condition of body can not only preferably be improved, additionally it is possible to which the effective muscle mass for increasing sarcopenia mouse is controlled
Muscle decay is treated and slowed down, the recovery of sarcopenia patient is facilitated.
Specific description of embodiments of the present invention above is not intended to limit the present invention, therefore is not departing from overall structure of the invention
Change and modification under thinking, should belong within protection scope of the present invention.
Claims (10)
1. a kind of medical food for treating and preventing old aged muscle decaying syndrome, which is characterized in that press the medical food
1000ml meter, include: protein 56-82g, fat 20-31g, carbohydrate 110-160g, dietary fiber 10.5-16.2g,
Beta-hydroxy-methylbutanoic acid calcium 0.9-1.6g, creatine 2.2-3.2g, vitamin 1.5-2.6g, minerals 20-30g and water 690-
800g;
Wherein, the protein include hydrolyzing lactoalbumin 22-36g, pea protein peptide 13-20g, wheat oligopeptide 13-20g,
Ocean fish oligopeptide powder 4.2-6.5g, leucine 1.6-2.5g;
The fat is sub- comprising medium chain triglyceride 7.2-11.5g, tea seed oil 5.5-8.5g, rapeseed oil 4.5-7.0g, conjugation
Oleic acid 1.5-2.5g, fish oil 2.0-3.5g;
The carbohydrate includes maltodextrin 70-105g, fructose 22-35g, resistant starch 13-20g;
The vitamin includes vitamin A 3.1-4.5mg, vitamin C 1.1-1.58g, vitamin D316.5-24 μ g, dimension life
Plain E 55-82mg, vitamin K11142-205 μ g, vitamin B14.2-6.5mg, vitamin B25.6-8.2mg, vitamin B6
5.6-8.2mg, pantothenic acid 13.9-21.2mg, biotin 8.5-12.5mg, folic acid 7.5-10.5mg, niacinamide 19.5-28.2mg,
Vitamin B126.2-8.9ug, choline 330-479mg;
The minerals include calcium chloride 2.4-3.6g, potassium hydroxide 0.3-0.49g, potassium citrate 0.96-1.55g, phosphoric acid hydrogen
Dipotassium 3.3-5.2g, sodium citrate 4.0-6.5g, magnesium chloride 2.1-3.2g, six hydrated chromium trichloride 13.5-18.6mg, glucose
Sour copper 18.2-28.5mg, three hydration ferrous lactate 80.5-118.2mg, Manganous sulfate monohydrate 11.2-17.9mg, two molybdic acid hydrates
Sodium 7.5-11.6mg, sodium selenite 26.6-40.2mg, Zinc sulfate monohydrate 40.9-60.5mg, 10% potassium iodide 2.8-4.2g.
2. the medical food according to claim 1 for treating and preventing old aged muscle decaying syndrome, which is characterized in that institute
Stating and treating and preventing the medical food of old aged muscle decaying syndrome includes protein 65g, fat 34.5g, carbohydrate
126g, dietary fiber 12.4g, vitamin 2.0g, minerals 24g, water 770g.
3. the medical food according to claim 2 for treating and preventing old aged muscle decaying syndrome, which is characterized in that institute
Stating protein includes hydrolyzing lactoalbumin 28g, pea protein peptide 15.2g, wheat oligopeptide 15.2g, leucine 2.0g.
4. the medical food according to claim 3 for treating and preventing old aged muscle decaying syndrome, which is characterized in that institute
It states fat and includes medium chain triglyceride 8.5g, tea seed oil 6.5g, rapeseed oil 5.3g, conjugated linoleic acid 1.9g, fish oil 2.5g.
5. the medical food according to claim 4 for treating and preventing old aged muscle decaying syndrome, which is characterized in that institute
Stating carbohydrate includes maltodextrin 85g, fructose 26g, resistant starch 15g;The treatment and prevention old aged muscle decaying
The medical food of syndrome also includes oligofructose 3.6g, xylo-oligosaccharide 3.6g, isomaltose 12.4g.
6. the medical food according to claim 5 for treating and preventing old aged muscle decaying syndrome, which is characterized in that institute
Stating vitamin includes vitamin A 3.62mg, vitamin C 1.26g, vitamin D319.2 μ g, vitamin E 64mg, vitamin K1
160 μ g, vitamin B14.8mg, vitamin B26.4mg, vitamin B66.4mg, pantothenic acid 16.64mg, biotin 9.6mg, leaf
Sour 8.0ug, niacinamide 22.4mg, vitamin B127.04 μ g, choline 380mg.
7. the medical food according to claim 6 for treating and preventing old aged muscle decaying syndrome, which is characterized in that institute
State minerals include calcium chloride 2.8g, potassium hydroxide 0.4g, potassium citrate 1.2g, dipotassium hydrogen phosphate 4.0g, sodium citrate 5.0g,
Magnesium chloride 2.5g, six hydrated chromium trichloride 14.35mg, copper gluconate 21.25mg, three hydration ferrous lactate 93.85mg, a water
Close manganese sulfate 14.0mg, two molybdic acid hydrate sodium 8.83mg, sodium selenite 32.2mg, Zinc sulfate monohydrate 48.03mg, 10% iodate
Potassium 3.3g.
8. the medical food according to claim 7 for treating and preventing old aged muscle decaying syndrome, which is characterized in that institute
Stating and treating and preventing the medical food of old aged muscle decaying syndrome includes beta-hydroxy-methylbutanoic acid calcium 1.2g and creatine 2.5g.
9. the medical food according to claim 8 for treating and preventing old aged muscle decaying syndrome, which is characterized in that institute
Stating and treating and preventing nutritional agents described in the medical food of old aged muscle decaying syndrome includes emulsifier soybean lecithin 1.1-1.8g,
Acidity regulator citric acid 1.7-2.6g, colorant natural Beta-carotene 0.7-1.2g.
10. a kind of prepare treats and prevents the medical of old aged muscle decaying syndrome described in any one in claim 1 to 9
Food, which comprises the following steps:
(1) aniseed dissolves: the pure water of total amount 65%-75% being added in dissolving tank, by solid original under strong Vibratory Mixing
Material is sequentially added into dissolving tank, so that feed liquid is flowed back uniformly by carrying out under liquid level, is uniformly dispersed in pure water, keeps away simultaneously
Exempt to generate excessive bubble and feed liquid layering, is constantly passed through nitrogen into lotion in entire process for preparation;
(2) oil is mutually prepared: oils raw material and liposoluble vitamin being mixed well dissolution in order, are heated to 40-60 DEG C;
(3) 60 DEG C or so progress homogeneous homogeneous: are cooled to after water phase is mutually mixed well with oil;
It (4) will be filling after the feed liquid cooling after homogeneous;
(5) terminal sterilization: product is placed in rotation, is sterilized in fountain sterilizing cabinet, 121 DEG C of sterilising temp, F0 value 8-12 is obtained
Finished product.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810791304.2A CN109077302A (en) | 2018-07-18 | 2018-07-18 | A kind of medical food and preparation method thereof treating and preventing old aged muscle decaying syndrome |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810791304.2A CN109077302A (en) | 2018-07-18 | 2018-07-18 | A kind of medical food and preparation method thereof treating and preventing old aged muscle decaying syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109077302A true CN109077302A (en) | 2018-12-25 |
Family
ID=64837766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810791304.2A Pending CN109077302A (en) | 2018-07-18 | 2018-07-18 | A kind of medical food and preparation method thereof treating and preventing old aged muscle decaying syndrome |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109077302A (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109527585A (en) * | 2018-12-26 | 2019-03-29 | 浙江华康药业股份有限公司 | A kind of alimentation composition and preparation method thereof that can prevent gentle expelling pathogenic factors from muscles and skin and lack disease |
CN110037297A (en) * | 2019-05-14 | 2019-07-23 | 宁波特壹食品有限公司 | A kind of formula powder and preparation method thereof of suitable sarcopenia |
CN111035017A (en) * | 2019-12-12 | 2020-04-21 | 山东省药学科学院 | Oral liquid for preventing and treating muscle loss |
CN112155057A (en) * | 2020-08-25 | 2021-01-01 | 石家庄君乐宝乳业有限公司 | High-protein thickened modified milk powder and preparation method thereof |
CN113412936A (en) * | 2021-07-14 | 2021-09-21 | 复旦大学附属中山医院 | Enteral nutrition preparation for sarcopenia patients |
CN114304287A (en) * | 2022-01-06 | 2022-04-12 | 江南大学 | Fat component used in medical formula food for sarcopenia syndrome, preparation method and application |
CN114431380A (en) * | 2022-02-25 | 2022-05-06 | 广东君悦营养医学有限公司 | Protein water suitable for muscle attenuation syndrome and preparation method thereof |
CN114680339A (en) * | 2022-04-12 | 2022-07-01 | 天津医科大学 | Nutritional supplement for improving muscle attenuation and delaying senescence and application thereof |
CN115177000A (en) * | 2021-04-07 | 2022-10-14 | 陕西罗麻丹医药有限公司 | Powder for improving sarcopenia of old people and preparation method thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1439299A (en) * | 2003-03-18 | 2003-09-03 | 华瑞制药有限公司 | Intestinal absorbing fully nutrient emulsion for phymatostio patient |
CN102665736A (en) * | 2009-12-24 | 2012-09-12 | N.V.努特里西阿公司 | Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis |
CN103079415A (en) * | 2010-07-07 | 2013-05-01 | N.V.努特里西阿公司 | Nutritional composition for the stimulation of muscle protein synthesis |
CN103338658A (en) * | 2010-12-22 | 2013-10-02 | 雅培制药有限公司 | Nutritional products comprising calcium beta-hydroxy-beta methylbutyrate and conjugated linoleic acid |
CN103766696A (en) * | 2013-12-26 | 2014-05-07 | 北京康比特体育科技股份有限公司 | Composition with muscle building function and preparation method thereof |
CN103783532A (en) * | 2012-10-29 | 2014-05-14 | 杭州纽曲星生物科技有限公司 | Compound protein powder for resisting age-related sarcopenia, and preparation methods thereof |
CN106072573A (en) * | 2016-07-05 | 2016-11-09 | 郑州和正生物科技有限公司 | A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible |
CN107927797A (en) * | 2017-12-11 | 2018-04-20 | 重庆市生物技术研究所有限责任公司 | It is a kind of to eat the wholefood formula containing small peptide for muscle decay syndrome crowd |
-
2018
- 2018-07-18 CN CN201810791304.2A patent/CN109077302A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1439299A (en) * | 2003-03-18 | 2003-09-03 | 华瑞制药有限公司 | Intestinal absorbing fully nutrient emulsion for phymatostio patient |
CN102665736A (en) * | 2009-12-24 | 2012-09-12 | N.V.努特里西阿公司 | Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis |
CN103079415A (en) * | 2010-07-07 | 2013-05-01 | N.V.努特里西阿公司 | Nutritional composition for the stimulation of muscle protein synthesis |
CN103338658A (en) * | 2010-12-22 | 2013-10-02 | 雅培制药有限公司 | Nutritional products comprising calcium beta-hydroxy-beta methylbutyrate and conjugated linoleic acid |
CN103783532A (en) * | 2012-10-29 | 2014-05-14 | 杭州纽曲星生物科技有限公司 | Compound protein powder for resisting age-related sarcopenia, and preparation methods thereof |
CN103766696A (en) * | 2013-12-26 | 2014-05-07 | 北京康比特体育科技股份有限公司 | Composition with muscle building function and preparation method thereof |
CN106072573A (en) * | 2016-07-05 | 2016-11-09 | 郑州和正生物科技有限公司 | A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible |
CN107927797A (en) * | 2017-12-11 | 2018-04-20 | 重庆市生物技术研究所有限责任公司 | It is a kind of to eat the wholefood formula containing small peptide for muscle decay syndrome crowd |
Non-Patent Citations (5)
Title |
---|
于健春: "《特殊医学用途配方食品临床应用指导》", 30 June 2016, 中华医学电子音像出版社 * |
缪琴等: "肠内营养制剂对肌肉衰减综合征患者肌力和肌含量的影响", 《全科医学临床与教育》 * |
蒋与刚等: "乳清蛋白与老年肌肉衰减征研究进展", 《中国食物与营养》 * |
谢琪: "老年肌肉衰减综合征营养干预研究进展", 《华夏医学》 * |
齐玉梅: "《特殊医学用途配方食品临床应用参考目录》", 31 August 2017, 中国医药科技出版社 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109527585A (en) * | 2018-12-26 | 2019-03-29 | 浙江华康药业股份有限公司 | A kind of alimentation composition and preparation method thereof that can prevent gentle expelling pathogenic factors from muscles and skin and lack disease |
CN110037297A (en) * | 2019-05-14 | 2019-07-23 | 宁波特壹食品有限公司 | A kind of formula powder and preparation method thereof of suitable sarcopenia |
CN111035017A (en) * | 2019-12-12 | 2020-04-21 | 山东省药学科学院 | Oral liquid for preventing and treating muscle loss |
CN112155057A (en) * | 2020-08-25 | 2021-01-01 | 石家庄君乐宝乳业有限公司 | High-protein thickened modified milk powder and preparation method thereof |
CN115177000A (en) * | 2021-04-07 | 2022-10-14 | 陕西罗麻丹医药有限公司 | Powder for improving sarcopenia of old people and preparation method thereof |
CN113412936A (en) * | 2021-07-14 | 2021-09-21 | 复旦大学附属中山医院 | Enteral nutrition preparation for sarcopenia patients |
CN114304287A (en) * | 2022-01-06 | 2022-04-12 | 江南大学 | Fat component used in medical formula food for sarcopenia syndrome, preparation method and application |
CN114304287B (en) * | 2022-01-06 | 2023-01-24 | 江南大学 | Fat component used in medical formula food for sarcopenia syndrome, preparation method and application |
CN114431380A (en) * | 2022-02-25 | 2022-05-06 | 广东君悦营养医学有限公司 | Protein water suitable for muscle attenuation syndrome and preparation method thereof |
CN114680339A (en) * | 2022-04-12 | 2022-07-01 | 天津医科大学 | Nutritional supplement for improving muscle attenuation and delaying senescence and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109077302A (en) | A kind of medical food and preparation method thereof treating and preventing old aged muscle decaying syndrome | |
CN108618129A (en) | Sarcopenia tailored version clinical nutrition formula and preparation method thereof | |
CN102438466B (en) | Human milk fortifier with high protein and long chain poly unsaturated fatty acids for improving body adipose tissue distribution | |
CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
RU2456985C2 (en) | Method for lean muscle mass gain and fatty tissue reduction | |
CN103458891A (en) | Nutritional composition | |
CN106172792A (en) | Alimentation composition is used for prophylactic purposes | |
CN108185437A (en) | A kind of full nutrient formulation powder of tumour and preparation method thereof | |
CN107951015A (en) | Full nutrient formulation powder and preparation method thereof | |
US20130045915A1 (en) | Method for weight loss and ketogenic compositions | |
CN107440088A (en) | Improve operation, the nutrients and preparation method thereof of chemicotherapy tumor patient immunity | |
AU2015310517A1 (en) | Optimized nutrient food | |
CN108348553A (en) | Using lactalbumin to improve or maintain the method for muscle quality | |
RU2687038C1 (en) | Nutritional compositions with different protein content corresponding to age requirements | |
CN108991506A (en) | A kind of not fibrous medical formula food of predigestion high energy and preparation method thereof | |
CN110301629A (en) | A kind of full nutrient solid beverage of tumor patient and preparation method thereof | |
CN105707707A (en) | Super quinoa nutrition powder for pregnant and lying-in women | |
CN107105752A (en) | Whey protein micelles are synthesized with the compound and human muscle's albumen of pectin | |
AU2007307964B2 (en) | Meal replacement compositions and weight control method | |
EP3010357B1 (en) | Administration of a food composition product | |
CN109090580A (en) | A kind of specific full nutritional formulas and preparation method thereof for tumor patient | |
JP3207823B2 (en) | Brown fat enhancer containing conjugated linoleic acid as active ingredient | |
CN105432792A (en) | Basic nutrition milk powder for preschool children, nutrition milk powder suit and preparation methods | |
TW201332555A (en) | Use of specific carbohydrate systems during pregnancy for reducing adverse health effects later in life in offspring | |
CN106573034A (en) | Marine peptides and fish nucleotides, compositions and uses thereof for reducing blood glucose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181225 |
|
RJ01 | Rejection of invention patent application after publication |